Trial
NCT01497275
Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Duke University
Collaborators
Spectrum Pharmaceuticals, Inc
Condition
Mantle-Cell Lymphoma
Intervention
Rituximab, Bortezomib,Y90 ibritumomab tiuxetan
Why stopped
Low accrual due to the approval of new drugs for use in Mantle cell lymphoma.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-07-15